KPIs & Operating Metrics(New)
Growth Metrics

Abbott Laboratories (ABT) Long-Term Deferred Tax (2016 - 2026)

Abbott Laboratories' Long-Term Deferred Tax history spans 16 years, with the latest figure at $18.4 billion for Q1 2026.

  • On a quarterly basis, Long-Term Deferred Tax rose 9.04% to $18.4 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $18.4 billion, a 9.04% increase, with the full-year FY2025 number at $18.4 billion, up 11.93% from a year prior.
  • Long-Term Deferred Tax hit $18.4 billion in Q1 2026 for Abbott Laboratories, roughly flat from $18.4 billion in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for ABT hit a ceiling of $18.4 billion in Q4 2025 and a floor of $5.4 billion in Q2 2022.
  • Historically, Long-Term Deferred Tax has averaged $10.4 billion across 5 years, with a median of $7.5 billion in 2024.
  • Biggest five-year swings in Long-Term Deferred Tax: soared 131.91% in 2024 and later grew 9.04% in 2026.
  • Tracing ABT's Long-Term Deferred Tax over 5 years: stood at $6.0 billion in 2022, then increased by 17.64% to $7.1 billion in 2023, then soared by 131.91% to $16.5 billion in 2024, then grew by 11.93% to $18.4 billion in 2025, then dropped by 0.35% to $18.4 billion in 2026.
  • Business Quant data shows Long-Term Deferred Tax for ABT at $18.4 billion in Q1 2026, $18.4 billion in Q4 2025, and $17.3 billion in Q3 2025.